Puma Biotechnology, Inc. (PBYI) Earnings History
Profitable19 years of earnings data (2007–2025) · Positive TTM net income
Loading earnings history...
Puma Biotechnology, Inc. (PBYI) Earnings Overview
As of June 22, 2026, Puma Biotechnology, Inc. (PBYI) reported trailing twelve-month net income of $24M, reflecting -1.6% year-over-year growth. The company earned $0.48 per diluted share over the past four quarters, with a net profit margin of 13.6%.
Looking at the long-term picture, PBYI's historical earnings data spans multiple years. The company achieved its highest annual net income of $31M in fiscal 2025, representing a new all-time high.
Puma Biotechnology, Inc. maintains positive profitability with a gross margin of 74.5%, operating margin of 16.3%, and net margin of 13.6%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), TGTX ($462M net income, 72.6% margin), PTCT (-$187M net income, 39.4% margin), PBYI has outperformed on profitability metrics. Compare PBYI vs RCUS →
PBYI Earnings vs Peers
Earnings metrics vs comparable public companies
PBYI Historical Earnings Data (2007–2025)
19 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $31M | +2.8% | $37M | $0.61 | 13.6% | 16.3% |
| 2024 | $30M | +40.2% | $31M | $0.62 | 13.1% | 13.4% |
| 2023 | $22M | +1079450.0% | $33M | $0.45 | 9.2% | 13.9% |
| 2022 | $2,000 | +100.0% | $24M | $0.02 | 0.0% | 10.4% |
| 2021 | -$29M | +51.5% | $1M | $-0.72 | -11.5% | 0.5% |
| 2020 | -$60M | +20.6% | -$30M | $-1.52 | -26.7% | -13.5% |
| 2019 | -$76M | +33.5% | -$76M | $-2.13 | -27.8% | -27.8% |
| 2018 | -$114M | +61.1% | -$95M | $-2.99 | -45.3% | -37.7% |
| 2017 | -$292M | -5.8% | -$292M | $-7.86 | -1054.2% | -1055.6% |
| 2016 | -$276M | -15.3% | -$277M | $-8.29 | - | - |
| 2015 | -$239M | -68.5% | -$240M | $-7.45 | - | - |
| 2014 | -$142M | -159.8% | -$142M | $-4.73 | - | - |
| 2013 | -$55M | +26.4% | -$55M | $-1.90 | - | - |
| 2012 | -$74M | -626.1% | -$74M | $-3.42 | - | - |
| 2011 | -$10M | -63951.6% | -$10M | $-0.51 | - | - |
| 2010 | $-15,976 | +5.1% | $-15,976 | $-0.01 | - | - |
| 2009 | $-16,836 | -19.5% | $-16,836 | $-0.01 | - | - |
| 2008 | $-14,083 | +99.9% | $-14,083 | $-0.00 | - | - |
| 2007 | -$15M | - | -$15M | $-0.38 | - | - |
Download Data
Export PBYI earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
19+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PBYI — Frequently Asked Questions
Quick answers to the most common questions about buying PBYI stock.
What is PBYI earnings per share (EPS)?
PBYI trailing twelve-month (TTM) diluted EPS is $0.48, reflecting -1.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2007 to 2025 is available in the table on this page.
What is Puma Biotechnology, Inc.'s net income?
Puma Biotechnology, Inc. (PBYI) trailing twelve-month net income is $24M as of 2025. Earnings declined -1.6% year-over-year. Puma Biotechnology, Inc. has been profitable for 4 consecutive years.
Is PBYI profitable?
Yes, PBYI is profitable with a TTM net income of $24M and a net profit margin of +13.6%. Puma Biotechnology, Inc. has generated profits for 4 consecutive years.
What is PBYI's earnings growth rate?
PBYI compound annual EPS growth rates (CAGR): 1-Year: -1.6%, 3-Year: +210.9%, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2007 to 2025.
What are PBYI's profit margins?
Puma Biotechnology, Inc. net profit margin is +13.6%, operating margin is +16.3%, and gross margin is +74.5%. Margins are within a typical range for the sector. Return on Equity is +28.0%.
Is PBYI growing earnings?
PBYI earnings growth is slowing. Current YoY EPS growth of -1.6% trails the 5-year CAGR of N/A. TTM net income is $24M.
What was PBYI's best earnings year?
Puma Biotechnology, Inc.'s highest annual net income on record is $31M, achieved in fiscal year 2025. Earnings history on this page spans 2007 to 2025 and includes all annual and quarterly figures.
What were PBYI's earnings last quarter?
PBYI's most recent reported quarter was Q1 2026. Net income was $-4M with diluted EPS of $-0.07. For a full breakdown of all quarters, see the quarterly earnings table on this page.